Abstract:Background: Crohn's disease (CD) is a progressive disorder resulting in chronic bowel inflammation. Though corticosteroid (CS) treatment typically controls acute flares, current guidelines support early initiation of biologic or immune therapy to prevent disease recurrence and complications. However, there is no consensus for how early such therapy should begin. Patients recovering from a hospitalization for an inflammatory disease flare responding to CS would seem to be ideal candidates for early initiation, though data to support this hypothesis is lacking. We performed an exploratory analysis among patients following uncomplicated CD hospitalization to investigate whether earlier biologic initiation post-discharge improved clinical outcomes. Methods: We retrospectively identified all patients admitted to Northwell Health's 4 tertiary care hospitals (LIJMC, North Shore University Hospital, Staten Island University Hospital, Lennox Hill) over the past 5 years with a primary diagnosis of CD flare, with CS-induced clinical response. All surgical admissions were excluded, as were patients with any prior biologic therapy, current abdominal abscess/phlegmon, perforation, and those without documented post-discharge follow-up. Early and late initiation of biologic/immune therapy was defined as occurring within 30 days or greater than 30 days from index admission respectively. We compared patients who initiated early vs late vs no biologic/immune therapy for adverse outcomes including CS use, readmission, and surgery within 1 year. Statistical analysis including chi-square, t-test, ANOVA, and linear regression was performed on IBM SPSS Statistics 26.0. Results: Of 415 patients screened, 367 were excluded (24 abscesses, 67 surgical interventions, 117 prior biologics, 86 nonflares, 1 clinical trial, 72 without outpatient follow-up) leaving 48 patients for analysis. Following discharge, 13 patients initiated biologic therapy within 30 days, 23 after 30 days and 12 did not initiate. Earlier biologic therapy trended towards decreased hospital readmissions and increased CS free remission at 1 year. 38.8% of the early initiation cohort had readmissions within 1 year compared to 43.5% in late initiation (OR = 0.578; 95% CI 0.137-2.433) and 58.3% in no initiation. 53.8% of the early initiation cohort remained CS free at 1 year compared to 52.2% in late initiation (OR = 1.07; 95% CI 0.27-4.18) and 36.4% in the no initiation group. At 1 year 8.3% of patients had surgery; 23.1% of the early initiators, 4.3% late initiators, and 0% non-initiators. Conclusion(s): Our analysis demonstrated a trend towards some improved outcomes for patients initiating early biologic/immune therapy following hospital discharge for inflammatory CD. The lack of statistical significance may be due to the small patient population analyzed, given the strict selection criteria. Since none of the patients were scored by validated severity scales such as the Crohn's Disease Activity Index, we could not measure or analyze by objective disease severity, though we suspect that those who received early biologic/immune therapy likely had more severe disease, as reflected by the one-year surgical rates. Our findings suggest the need for larger retrospective work and even prospective studies to better define the optimal timing and potential benefit of early biologic/immune therapy following severe CD flare.

P711 Outcomes of Outpatient Biologic Exposed Patients Hospitalized with Severe Ulcerative Colitis

P550 Short and long-term outcomes after acute severe ulcerative colitis in adults: A 12 year Canadian experience in the post biologic era

P664 Anti-TNF exposure is associated with an increased risk of urgent and one-year colectomy in Acute Severe Ulcerative Colitis

Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort

Analysis on Short-and Long-Term Outcomes of Acute Severe Ulcerative Colitis

P822 Therapeutic Management And Risk Of Colectomy In Patients With Acute Severe Ulcerative Colitis And Previous Exposure To Anti-Tnf Drugs. A Cohort Study Of Geteccu

P972 Short and long-term outcomes after acute severe ulcerative colitis in children: A Canadian single centre experience

P907 Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s Disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis

P340 The association between colon pseudopolyps presence and clinical adverse events in UC patients treated with biologics

THE IMPACT OF TREATMENT SWITCH AMONG PATIENTS WITH ULCERATIVE COLITIS NEWLY TREATED WITH A BIOLOGIC – A JAPAN RETROSPECTIVE CLAIMS DATABASE STUDY

P1001 Predictive factors of colectomy in patients admitted with Acute Severe Ulcerative Colitis

P577 Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

OP12 Does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRN

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY

Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis

Opioid Use and Outcomes in Patients Hospitalized With Acute Severe Ulcerative Colitis

S73 Impact of Early Biologic Therapy Initiation Following Crohn’s Disease Hospitalization: A Multicenter Retrospective Analysis

P662 Discontinuation of biologic therapy in Inflammatory Bowel Disease: longer term outcomes

P297 Differences in disease characteristics and treatment exposures between pediatric- and adult-onset Ulcerative Colitis

Endoscopic healing is associated with a reduced risk of biologic treatment failure in patients with ulcerative colitis

P1054 Clinical outcomes for ulcerative colitis patients stopping 5-aminosalicylates starting biologics and/or immunomodulator therapy: A Systematic review and meta-analysis